Section 3: Production and Compounding

3PC-047

EVALUATION OF THE EFFECTIVENESS AND SATISFACTION OF THE MASTER SUSPENSION FORMULA FOR MUCOSITIS ELABORATED IN A TERTIARY HOSPITAL

3PC-046

STUDY OF STABILITY OF TWO LIQUID FORMULATIONS OF OMEPRAZOLE ELABORATED IN THE PHARMACEUTICAL SERVICE

3PC-045

FORMULATION AND STABILITY STUDY OF EXTEMPORANEOUS ORAL LIQUID DOSAGE FORMS CONTAINING FLECAINIDE ACETATE 2MG/ML FOR PAEDIATRIC USE

3PC-044

PARAFFIN OIL-BASED EMULSION: INFLUENCE OF GUM ARABIC AND THE MIXING RATE ON EMULSION STABILITY

3PC-043

NEW FORMULATION OF NOREPINEPHRINE SOLUTION IN PREFILLED CYCLIC OLEFIN STERILISED SYRINGES

3PC-042

A SCIENCE- AND RISK-BASED STRATEGY TO QUALIFY STERILISED PREFILLED SYRINGES AS PRIMARY PACKAGING MATERIAL IN A HOSPITAL PHARMACY

3PC-041

AUTOMATION OF PARENTERAL NUTRITION COMPOUNDING: RESULTS OF GRAVIMETRIC QUALITY CONTROL BEFORE AND AFTER ITS IMPLEMENTATION

3PC-040

HEALTH HAZARDS OF RAW MATERIALS USED IN THE COMPOUNDING OF PHARMACEUTICALS FORMULATIONS

3PC-039

STABILITY STUDY OF (99MTC)DOTATOC AND (68GA)DOTATOC IN SYRINGES

3PC-038

ABSTRACT WITHDRAWN

3PC-037

DEVELOPMENT OF VIRTUAL DRUG INFORMATION CENTRE FOR PHARMACY COMPOUNDING AREA

3PC-036

COMPARISON OF METABOLITE LEVELS IN SERUM AND TEARS: IMPLICATIONS FOR THE DILUTION OF AUTOLOGOUS-SERUM-EYE-DROPS

3PC-035

GALENIC FORMULATIONS FOR OPHTALMOLOGISTS: NEW FORMULATIONS, PRESCRIBING PATHWAYS AND PATIENT INFORMATION

3PC-034

IMIPENEM-FORTIFIED EYE DROPS FOR THE TREATMENT OF BACTERIAL KERATITIS: DEVELOPMENT AND CHARACTERISATION

3PC-033

LABELLING WITHOUT STRENGTH FOR A PHARMACEUTICAL PREPARATION USED IN A BLINDED DOSAGE ADJUSTMENT OF CLOZAPINE

Pages